Patented technology for the production of full-length, correctly folded and functional proteins
Identify all autoantigens and antigens that make up the Autoproteome*
(*) Totality of all possible autoantigens and neoantigens representing a given disease and its sub-types
Sengenics offers KREX for use in the discovery, validation, screening and development of new therapeutics through the use of discovery based KREX-based platforms. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.
Examples of using KREX for discovery of potential therapeutics:
High-throughput autoantibody profiling against 1600+ proteins
Quantification of autoantibodies to 200+ clinically relevant CT antigens
Simultaneous screening of 100+
wild-type and mutant p53
Multi-antigen, multi-domain
COVID-19 antibody test
